- Home
- KNSA
as of 02-04-2026 3:52pm EST
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
| Founded: | 2015 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 2.6B | IPO Year: | 2018 |
| Target Price: | $52.33 | AVG Volume (30 days): | 671.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.12 - $45.50 | Next Earning Date: | 02-24-2026 |
| Revenue: | $597,973,000 | Revenue Growth: | 55.68% |
| Revenue Growth (this year): | 62.7% | Revenue Growth (next year): | 31.18% |
AI-Powered KNSA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Kiniksa Pharmaceuticals Ltd. (KNSA)
Director
Avg Cost/Share
$45.02
Shares
2,602
Total Value
$117,142.04
Owned After
12,546
SEC Form 4
Director
Avg Cost/Share
$45.27
Shares
12,528
Total Value
$567,142.56
Owned After
12,546
SEC Form 4
Director
Avg Cost/Share
$45.00
Shares
830
Total Value
$37,350.00
Owned After
12,546
SEC Form 4
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$41.89
Shares
12,000
Total Value
$502,680.00
Owned After
19,086
SEC Form 4
CHIEF OPERATING OFFICER
Avg Cost/Share
$41.56
Shares
12,048
Total Value
$500,714.88
Owned After
16,666
SEC Form 4
Director
Avg Cost/Share
$41.51
Shares
20,129
Total Value
$835,554.79
Owned After
12,546
SEC Form 4
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$41.49
Shares
42,841
Total Value
$1,777,473.09
Owned After
19,086
SEC Form 4
CHIEF OPERATING OFFICER
Avg Cost/Share
$42.89
Shares
200
Total Value
$8,578.00
Owned After
16,666
SEC Form 4
CHIEF OPERATING OFFICER
Avg Cost/Share
$40.69
Shares
12,470
Total Value
$514,224.10
Owned After
16,666
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$40.94
Shares
19,900
Total Value
$814,706.00
Owned After
19,086
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Quart Barry D | KNSA | Director | Feb 4, 2026 | Sell | $45.02 | 2,602 | $117,142.04 | 12,546 | |
| Quart Barry D | KNSA | Director | Feb 3, 2026 | Sell | $45.27 | 12,528 | $567,142.56 | 12,546 | |
| Quart Barry D | KNSA | Director | Feb 2, 2026 | Sell | $45.00 | 830 | $37,350.00 | 12,546 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Jan 8, 2026 | Sell | $41.89 | 12,000 | $502,680.00 | 19,086 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Dec 15, 2025 | Sell | $41.56 | 12,048 | $500,714.88 | 16,666 | |
| Quart Barry D | KNSA | Director | Dec 15, 2025 | Sell | $41.51 | 20,129 | $835,554.79 | 12,546 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Dec 8, 2025 | Sell | $41.49 | 42,841 | $1,777,473.09 | 19,086 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Nov 26, 2025 | Sell | $42.89 | 200 | $8,578.00 | 16,666 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Nov 17, 2025 | Sell | $40.69 | 12,470 | $514,224.10 | 16,666 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Nov 12, 2025 | Sell | $40.94 | 19,900 | $814,706.00 | 19,086 |
Compare KNSA vs Leading Stocks
See how KNSA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "KNSA Kiniksa Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.